Kura Oncology (NASDAQ:KURA) Earns Market Outperform Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Tuesday, Benzinga reports. JMP Securities currently has a $32.00 target price on the stock.

Several other analysts have also commented on KURA. HC Wainwright restated a buy rating and set a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, May 14th. StockNews.com lowered shares of Kura Oncology from a hold rating to a sell rating in a research report on Monday, April 15th. Finally, Wedbush reiterated an outperform rating and issued a $37.00 target price on shares of Kura Oncology in a research report on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $28.36.

Kura Oncology Stock Up 3.1 %

KURA stock opened at $20.94 on Tuesday. The firm has a market cap of $1.60 billion, a PE ratio of -9.65 and a beta of 0.94. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67. The firm’s fifty day moving average is $20.57 and its 200 day moving average is $18.94. Kura Oncology has a one year low of $7.41 and a one year high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03). The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.50) EPS. On average, research analysts forecast that Kura Oncology will post -2.56 EPS for the current year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 2,615 shares of Kura Oncology stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $22.15, for a total transaction of $57,922.25. Following the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,527,884.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the stock. Signaturefd LLC raised its stake in shares of Kura Oncology by 40.4% in the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after acquiring an additional 1,449 shares during the period. Pale Fire Capital SE acquired a new position in shares of Kura Oncology in the third quarter valued at approximately $92,000. SG Americas Securities LLC acquired a new position in Kura Oncology during the 1st quarter worth approximately $110,000. AXQ Capital LP acquired a new position in Kura Oncology during the 3rd quarter worth approximately $118,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Kura Oncology by 352.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after acquiring an additional 6,692 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.